Acurastem Says Deal With Takeda To Develop And Commercialize Pikfyve Targeted Therapeutics Including AS-202, ASO To Treat ALS
Portfolio Pulse from Benzinga Newsdesk
Acurastem has announced a deal with Takeda to develop and commercialize Pikfyve targeted therapeutics, including AS-202, an antisense oligonucleotide (ASO) to treat ALS.
September 25, 2023 | 2:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Takeda's partnership with Acurastem to develop and commercialize Pikfyve targeted therapeutics could potentially enhance its product portfolio and future revenue streams.
The partnership with Acurastem allows Takeda to expand its product portfolio with the development of Pikfyve targeted therapeutics, including AS-202 for ALS treatment. This could potentially lead to new revenue streams, positively impacting Takeda's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100